B
BMX
vs
W
WIG20
Over the past 12 months, BMX has underperformed WIG20, delivering a return of -11% compared to the WIG20's +29% growth.
Stocks Performance
BMX vs WIG20
Performance By Year
BMX vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
